Jihoon Kang
Co-Chief Executive Officer ONCOCROSS
Dr. Jihoon Kang, M.D., Ph.D., is Co-Chief Executive Officer of ONCOCROSS, an AI-driven biotechnology company developing multi-omics-enabled approaches to accelerate therapeutic discovery, indication expansion and drug development. A medical oncologist by training, he previously served as Vice President and Chief Medical Officer of ONCOCROSS and as an Assistant Professor in Hematology and Oncology at Kangbuk Samsung Hospital. He completed his medical oncology fellowship and internal medicine residency at Asan Medical Center and undertook a visiting scholarship in developmental therapeutics at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Kang brings together expertise in clinical oncology, translational research, and drug-development leadership to advance AI- and human multi-omics-driven therapeutic programs from biological hypothesis generation toward clinical translation.
Seminars
- Tracing how RAPTOR AI v1.0 platform translated transcriptomic signatures into prioritized drug, indication, and combination-therapy hypotheses for experimental evaluation and clinical development
- Assessing experimental and early clinical evidence from OC212e to examine how the transcriptomic hypothesis translated into a clinically relevant program and how insights informed RAPTOR platform evolution
- Introducing RAPTOR AI v2.0 to integrate clinically annotated, human samplederived proteomic and multi-omic data to support modality-specific target discovery, target-pair selection and therapeutic development
